Zenagamtide compared with semaglutide for type 2 diabetes not controlled by current treatment
Compares zenagamtide with semaglutide in adults with type 2 diabetes on metformin or SGLT2i.
Plain-language title generated from the registry record
Registry title: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Key facts
- Where
- Bad Oeynhausen, Berlin, Duisburg, Falkensee, Gladbeck, Hamburg, Köln-Dünnwald, Leipzig, Münster, Pirna, Pohlheim, Reinfeld, and Villingen-Schwenningen, GermanySee the 13 sites
- Phase
- Phase 3
Where in Germany
- Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet BochumBad Oeynhausen, GermanyNot yet recruiting
- Medizinisches Versorgungszentrum Am Bahnhof Spandau GbRBerlin, GermanyNot yet recruiting
- MVZ Hausaerzte Grossenbaum GmbHDuisburg, GermanyNot yet recruiting
- Zentrum für klinische Forschung, Dr. med. LüdemannFalkensee, GermanyNot yet recruiting
- Hausarztzentrum ButendorfGladbeck, GermanyNot yet recruiting
- Diabeteszentrum Hamburg WestHamburg, GermanyNot yet recruiting
- Zentrum für Klinische Forschung Köln-DünnwaldKöln-Dünnwald, GermanyNot yet recruiting
- Gemeinschaftspraxis Dr. Täschner/Dr. BonigutLeipzig, GermanyNot yet recruiting
- Schwerpunktpraxis für Diabetes und ErnährungsmedizinMünster, GermanyNot yet recruiting
- Hausärztliche und Diabetologische Praxis PirnaPirna, GermanyNot yet recruiting
- Centrum Fuer Diabetologie Und AllgemeinmedizinPohlheim, GermanyNot yet recruiting
- Praxis Reinfeld MitteReinfeld, GermanyNot yet recruiting
- Praxis für Prävention und Therapie, Drs JacobVillingen-Schwenningen, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07931573EU 2026-525472-26-00
- Record updated
- 12 November 2026
- Original description
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will get one of the following: Zenagamtide (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator).Read full original descriptionShow less
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Higher Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both (AMBITION 3)
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will get one of the following: Zenagamtide (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator).
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent; Diagnosed with type 2 diabetes (T2D) above or equal to 180 days before screening; On stable daily dose(s) of metformin, sodium-glucose transport 2 (SGLT2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening; Glycated haemoglobin (HbA1c) as determined by central laboratory at screening.
Exclusion: Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening; Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days; Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening; Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation; Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening; Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method; Planned coronary, carotid or peripheral artery revascularisation.